TC
GSK icon

Truvestments Capital’s GSK GSK Stock Holding History

Truvestments Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.6K Sell
1,481
-220
-13% -$11.6K 0.01% 455
2026
Q1 		$93.9K Buy
1,701
+51
+3% +$2.76K 0.02% 393
2025
Q4 		$80.9K Hold
1,650
– – 0.01% 373
2025
Q3 		$71.2K Sell
1,650
-170
-9% -$6.64K 0.01% 394
2025
Q2 		$69.9K Buy
1,820
+1,065
+141% +$40.7K 0.01% 338
2025
Q1 		$29.2K Buy
755
+130
+21% +$4.76K 0.01% 489
2024
Q4 		$21.1K Buy
625
+199
+47% +$7.16K 0.01% 492
2024
Q3 		$17.4K Buy
+426
New +$17.4K ﹤0.01% 511
2024
Q2 		– Sell
-232
Closed -$9.95K – 416
2024
Q1 		$9.95K Hold
232
– – ﹤0.01% 500
2023
Q4 		$8.6K Hold
232
– – ﹤0.01% 529
2023
Q3 		$8.41K Hold
232
– – ﹤0.01% 463
2023
Q2 		$8.27K Sell
232
-722
-76% -$25.9K ﹤0.01% 469
2023
Q1 		$33.9K Buy
954
+722
+311% +$25.3K 0.02% 329
2022
Q4 		$8.15K Buy
+232
New +$7.73K ﹤0.01% 486
2022
Q3 		– Sell
-393
Closed -$21K – 639
2022
Q2 		$21K Buy
+393
New +$21.7K 0.01% 336
2022
Q1 		– Sell
-393
Closed -$22K – 328
2021
Q4 		$22K Hold
393
– – 0.01% 338
2021
Q3 		$19K Hold
393
– – 0.01% 322
2021
Q2 		$20K Sell
393
-1,113
-74% -$53.5K 0.01% 320
2021
Q1 		$68K Buy
1,506
+553
+58% +$25.1K 0.04% 251
2020
Q4 		$44K Sell
953
-688
-42% -$31.6K 0.03% 279
2020
Q3 		$77K Sell
1,641
-213
-11% -$10.7K 0.07% 164
2020
Q2 		$94K Sell
1,854
-90
-5% -$4.62K 0.1% 156
2020
Q1 		$92K Buy
+1,944
New +$104K 0.12% 129
2019
Q4 		– Sell
-2,428
Closed -$130K – 320
2019
Q3 		$130K Sell
2,428
-60
-2% -$3.09K 0.08% 162
2019
Q2 		$124K Sell
2,488
-729
-23% -$36.6K 0.08% 165
2019
Q1 		$168K Buy
+3,217
New +$161K 0.13% 119
2018
Q3 		$218K Buy
+4,344
New +$221K 0.1% 170

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Truvestments Capital's GSK Position: Q2 2026 in Review

Truvestments Capital reduced its GSK (GSK) stake by 13% in Q2 2026, selling an estimated $11.6K and leaving 1,481 shares worth $77.6K. The position accounts for 0.01% of the portfolio, ranked #455.

Truvestments Capital first reported a position in GSK in Q3 2018 and has held it in 27 quarters since. The position peaked at $218K in Q3 2018. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Truvestments Capital held 1,481 shares of GSK worth $77.6K as of Q2 2026.
  • Truvestments Capital sold 220 GSK shares in Q2 2026, an estimated $11.6K.
  • GSK made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #455 holding.
  • Truvestments Capital first reported a position in GSK in Q3 2018 and has held it in 27 quarters since.
  • Truvestments Capital's GSK position peaked at $218K in Q3 2018.
  • 1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.